8-(3-(<i>R</i>)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
Matthias Eckhardt(University of Bonn), Frank Himmelsbach(Boehringer Ingelheim (Germany)), Moh Tadayyon(Boehringer Ingelheim (Germany)), Peter Sieger(Boehringer Ingelheim (Germany)), Waldemar Pfrengle(Boehringer Ingelheim (Germany)), Herbert Nar(Boehringer Ingelheim (Germany)), Leo Thomas(Boehringer Ingelheim (Germany)), Ralf Lotz(Boehringer Ingelheim (Germany)), Michael Mark(Boehringer Ingelheim (Germany)), Elke Langkopf(Boehringer Ingelheim (Germany)), Brian D. Guth(Boehringer Ingelheim (Germany)), Holger Fuchs(Boehringer Ingelheim (Germany))
Cited by 285
Related Papers
Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5·5 and pH 9·0
|Journal of Molecular Biology|1991|487
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors
|Journal of Medicinal Chemistry|2002|454
Biophysics in drug discovery: impact, challenges and opportunities
|Nature Reviews Drug Discovery|2016|383
Adult Ceramide Synthase 2 (CERS2)-deficient Mice Exhibit Myelin Sheath Defects, Cerebellar Degeneration, and Hepatocarcinomas
|Journal of Biological Chemistry|2009|303